newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMX
  • CytomX Therapeutics, Inc. appointed Alejandra Carvajal as Chief Legal Officer on August 3, 2026.
  • Carvajal will support the company's strategic, operational, & pipeline initiatives while strengthening its leadership team.
  • She brings over two decades of legal expertise, most recently serving as SVP, Chief Legal Officer, & Secretary at Mersana Therapeutics during its acquisition by Day One Biopharmaceuticals.
  • Her prior experience includes roles as Chief Legal Officer at Momenta Pharmaceuticals (acquired by Johnson & Johnson), General Counsel at Cerulean Pharma, & positions at Millennium Pharmaceuticals.
  • Carvajal holds a J.D. from Georgetown University Law Center & an A.B. from Harvard University, & currently serves on the Board of Directors of the Science Club for Girls.
  • CytomX is a clinical-stage oncology company developing masked, conditionally activated PROBODY® therapeutics to target the tumor microenvironment.
  • The company's clinical pipeline includes Varseta-M (CX-2051), a PROBODY® ADC for metastatic colorectal cancer discovered with ImmunoGen, & CX-801, a PROBODY® cytokine for metastatic melanoma.
  • Strategic collaborations exist with major oncology leaders including Amgen, Regeneron, & Moderna.